Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?

Journal of Clinical Oncology

Volumn 32, Issue 13, 2014, Pages 1299-1301

  Giannarini, Gianluca ^a   Gandaglia, Giorgio ^b   Montorsi, Francesco ^b   Briganti, Alberto ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER SPHINCTER; CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOCAL THERAPY; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLEASON SCORE; HUMAN; INTERMEDIATE RISK PATIENT; LETHALITY; LOW RISK PATIENT; LYMPH NODE METASTASIS; MORBIDITY; NOTE; ORGAN PRESERVATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SOLID TUMOR; ABLATION THERAPY; ARTICLE; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR;

ABLATION TECHNIQUES; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84902595229     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.8214     Document Type: Note

References (17)

1. Valerio M, Ahmed HU, Emberton M, et al: The role of focal therapy in the management of localised prostate cancer: A systematic review. Eur Urol 10.1016/j.eururo. 2013.05.048 [epub ahead of print on June 6, 2013]
2. Ahmed HU: The index lesion and the origin of prostate cancer. N Engl J Med 361:1704-1706, 2009
3. Liu W, Laitinen S, Khan S, et al: Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15:559-565, 2009
4. Haffner MC, Mosbruger T, Esopi DM, et al: Tracking the clonal origin of lethal prostate cancer. J Clin Invest 123:4918-4922, 2013
5. Mouraviev V, Villers A, Bostwick DG, et al: Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: Active surveillance and focal targeted therapy. BJU Int 108:1074-1085, 2011
6. Briganti A, Tutolo M, Suardi N, et al: There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology: Implications for focal therapies. Prostate 72:925-930, 2012
7. Moore CM, Robertson NL, Arsanious N, et al: Image-guided prostate biopsy using magnetic resonance imaging-derived targets: A systematic review. Eur Urol 63:125-140, 2013
8. Arumainayagam N, Ahmed HU, Moore CM, et al: Multiparametric MR imaging for detection of clinically significant prostate cancer: A validation cohort study with transperineal template prostate mapping as the reference standard. Radiology 268:761-769, 2013
9. de la Rosette J, Ahmed H, Barentsz J, et al: Focal therapy in prostate cancer: Report from a consensus panel. J Endourol 24:775-780, 2010
10. Singh PB, Anele C, Dalton E, et al: Prostate cancer tumour features on template prostate-mapping biopsies: Implications for focal therapy. Eur Urol 10.1016/j.eururo. 2013.09.045 [epub ahead of print on October 6, 2013]
11. Klotz L, Zhang L, Lam A, et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-131, 2010
12. Wilt TJ, Brawer MK, Jones KM, et al: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203-213, 2012
13. Ji J, Yuan H, Wang L, et al: Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk? A single center prospective study. J Surg Res 178:779-784, 2012
14. Heidenreich A, Bastian PJ, Bellmunt J, et al: EAU guidelines on prostate cancer: Part 1. Screening, diagnosis, and local treatment with curative intent - Update 2013. Eur Urol 65:124-137, 2014
15. Zumsteg ZS, Spratt DE, Pei I, et al: A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 64:895-902, 2013
16. Barret E, Ahallal Y, Sanchez-Salas R, et al: Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 63:618-622, 2013
17. Salonia A, Burnett AL, Graefen M, et al: Prevention and management of postprostatectomy sexual dysfunctions: Part 1. Choosing the right patient at the right time for the right surgery. Eur Urol 62:261-272, 2012